{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:33:50Z","timestamp":1760866430406,"version":"3.41.2"},"reference-count":46,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational All"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Allergic rhinitis (AR) is an inflammatory disorder triggered by an allergic immune response to inhaled allergens. Birch pollen is the major allergenic tree pollen in parts of Europe. ITULAZAX\u00ae is a sublingual immunotherapy tablet for the treatment of adults with moderate\u2010to\u2010severe AR and\/or conjunctivitis induced by pollen from the birch homologous group. The aim was to compare the costs of treating AR with ITULAZAX\u00ae versus subcutaneous ALUTARD SQ\u00ae <jats:italic>Betula verrucosa<\/jats:italic> (ALUTARD SQ\u00ae) from a Danish societal perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cost\u2010minimization model was developed to capture costs of allergy immunotherapy (AIT), interactions with healthcare professionals (HCPs) in three different care settings (general practice, allergy specialist, and hospital), and indirect costs arising from absenteeism and presenteeism. The cost\u2010minimization analysis was conducted over a 3\u2010year time horizon with costs reported in 2021 Danish Kroner (DKK) and Euros (EUR) based on the European Central Bank 365\u2010day average exchange rate. One\u2010way sensitivity analyses were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The base case analysis showed that the total cost of treatment over 3\u00a0years was estimated to be DKK 49,117 (EUR 6598) per patient with ALUTARD SQ\u00ae, compared with DKK 30,996 (EUR 4164) with ITULAZAX\u00ae, reflecting a cost saving of DKK 18,121 (EUR 2434) per patient with ITULAZAX\u00ae over 3\u00a0years. Over the 3\u2010year time horizon, costs of AIT were predicted to increase by DKK 17,928 (EUR 2408) with ITULAZAX\u00ae, while costs of interactions with HCPs were predicted to decrease by DKK 22,528 (EUR 3027) versus ALUTARD SQ\u00ae, more than offsetting the increased cost of ITULAZAX\u00ae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Given the equivalent effectiveness of the two AIT products, and the cost savings with ITULAZAX\u00ae versus ALUTARD SQ\u00ae from a Danish societal perspective, ITULAZAX\u00ae should be considered as a cost\u2010saving alternative to ALUTARD SQ\u00ae for the treatment of birch pollen\u2010induced moderate\u2010to\u2010severe AR in adults.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clt2.12196","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:53:18Z","timestamp":1667469198000},"source":"Crossref","is-referenced-by-count":1,"title":["ITULAZAX<sup>\u00ae<\/sup> versus Alutard SQ<sup>\u00ae<\/sup> in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost\u2010minimization modeling analysis from the Danish societal perspective"],"prefix":"10.1002","volume":"12","author":[{"given":"Steen M.","family":"R\u00f8nborg","sequence":"first","affiliation":[{"name":"Allergy and Pulmonology Clinic  Vanl\u00f8se Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias Sydendal","family":"Grand","sequence":"additional","affiliation":[{"name":"ALK\u2010Abell\u00f3 A\/S  H\u00f8rsholm Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Brandi","sequence":"additional","affiliation":[{"name":"ALK\u2010Abell\u00f3 A\/S  H\u00f8rsholm Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Covalence Research Ltd  Harpenden UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"European Academy of Allergy and Clinical Immunology (EAACI).Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis;2015. Accessed 26 October 2021.http:\/\/patients.eaaci.org\/global\u2010atlases\/"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2012.26.3762"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2014.35.3794"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.010"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398\u20109995.2002.23664.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.183095"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121701"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465\u20109921\u20106\u2010153"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(08)61446\u20104"},{"volume-title":"WAO White Book on Allergy: Update 2013","year":"2013","author":"World Allergy Organization (WAO)","key":"e_1_2_9_11_1"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882\u2010018\u20100781\u2010y"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000151243"},{"key":"e_1_2_9_14_1","unstructured":"European Medicines Agency (EMA).Guideline on Allergen Products: Production and Quality IssuesEMEA\/CHMP\/BWP\/304831\/2007;2008. Accessed 26 October 2021.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010allergen\u2010products\u2010production\u2010quality\u2010issues_en.pdf"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398\u20109995.2007.01393.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.050"},{"key":"e_1_2_9_17_1","unstructured":"Data on File. Integrated Clinical Trial Report. Efficacy and Safety of the SQ Tree SLIT\u2010Tablet in Subjects with Moderate to Severe Allergic Rhinitis And\/or Conjunctivitis Induced by Pollen from the Birch Group. Trial ID: TT\u201004 2018."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.1001"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561\u2010016\u20100110\u2010x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12948\u2010016\u20100049\u20109"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1398\u20109995.2003.00387.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12112"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.09.018"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1308208"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1939\u20104551\u20107\u20106"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010017\u20100516\u20101"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1158718"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_2_9_30_1","unstructured":"European Academy of Allergy and Clinical Immunology (EAACI).Allergen Immunotherapy Guidelines. Part 2: Recommendations. Accessed 21 October 2021.https:\/\/medialibrary.eaaci.org\/mediatheque\/media.aspx?mediaId=60223%26channel=8518"},{"key":"e_1_2_9_31_1","unstructured":"L\u00e6geforeningen.Takstkort 11A.2021.https:\/\/www.laeger.dk\/sites\/default\/files\/oenh_takstkort_pr_011021.pdfAccessed October 21 2021."},{"key":"e_1_2_9_32_1","unstructured":"Sundhedsdatastyrelsen.Takstsystem 2020.2021.https:\/\/sundhedsdatastyrelsen.dk\/\u2010\/media\/sds\/filer\/finansiering\u2010og\u2010afregning\/takster\/2021\/takstvejledning\u20102021.pdfAccessed October 21 2021."},{"key":"e_1_2_9_33_1","unstructured":"Honorartabel L\u00e6geforeningen.Overenskomst om almen praksis. Accessed 21 October 2021.https:\/\/www.laeger.dk\/sites\/default\/files\/honorartabel_2021_oktober.pdf"},{"key":"e_1_2_9_34_1","unstructured":"L\u00e6gemiddelstyrelsen. Medicinpriser.dk.www.medicinpriser.dk"},{"key":"e_1_2_9_35_1","unstructured":"European Central Bank.ECB Euro Reference Exchange Rate: Danish Krone (DKK).https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/euro_reference_exchange_rates\/html\/eurofxref\u2010graph\u2010dkk.en.html"},{"key":"e_1_2_9_36_1","unstructured":"Statistik Danmarks.Hovedtabel personindkomster efter indkomsttype k\u00f8n alder population prisenhed og enhed (LONS20). Accessed 21 October 2021.https:\/\/www.statistikbanken.dk\/statbank5a\/SelectVarVal\/Define.asp?MainTable=INDKP201%26PLanguage=0%26PXSId=0%26wsid=cftree"},{"key":"e_1_2_9_37_1","unstructured":"Statistik Danmarks.Fuldtidsledige i pct. af arbejdsstyrken (forel\u00f8big opg\u00f8relse) efter omr\u00e5de alder og k\u00f8n (AUP01). Accessed 21 October 2021.https:\/\/www.statistikbanken.dk\/statbank5a\/SelectVarVal\/Define.asp?MainTable=AUP01%26PLanguage=0%26PXSId=0%26wsid=cftree"},{"key":"e_1_2_9_38_1","unstructured":"Organisation for Economic Co\u2010operation and Development.Pensions at a Glance 2017: Country Profiles \u2013 Denmark. Accessed 21 October 2021.https:\/\/www.oecd.org\/els\/public\u2010pensions\/PAG2017\u2010country\u2010profile\u2010Denmark.pdf"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.999"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s122948"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7003.485"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7387.475"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0000000000000335"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.10.027"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0091\u20106749(99)70370\u20102"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091\u20106749(92)90130\u2010t"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s122948"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.12196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clt2.12196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.12196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T10:02:29Z","timestamp":1692439349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.12196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/clt2.12196"],"URL":"https:\/\/doi.org\/10.1002\/clt2.12196","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"type":"print","value":"2045-7022"},{"type":"electronic","value":"2045-7022"}],"subject":[],"published":{"date-parts":[[2022,11]]},"article-number":"e12196"}}